Acharya Narottam, Talawar Ramappa K, Saikrishnan K, Vijayan M, Varshney Umesh
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, 560 012, India.
Nucleic Acids Res. 2003 Dec 15;31(24):7216-26. doi: 10.1093/nar/gkg918.
Uracil DNA glycosylase (UDG), a ubiquitous and highly specific enzyme, commences the uracil excision repair pathway. Structural studies have shown that the tyrosine in a highly conserved GQDPY water-activating loop of UDGs blocks the entry of thymine or purines into the active site pocket. To further understand the role of this tyrosine (Y66 in Escherichia coli UDG), we have overproduced and characterized Y66F, Y66H, Y66L and Y66W mutants. The complexes of the wild-type, Y66F, Y66H and Y66L UDGs with uracil DNA glycosylase inhibitor (Ugi) (a proteinaceous substrate mimic) were stable to 8 M urea. However, some dissociation of the complex involving the Y66W UDG occurred at this concentration of urea. The catalytic efficiencies (V(max) / K(m)) of the Y66L and Y66F mutants were similar to those of the wild-type UDG. However, the Y66W and Y66H mutants were approximately 7- and approximately 173-fold compromised, respectively, in their activities. Interestingly, the Y66W mutation has resulted in an enzyme which is resistant to product inhibition. Preferential utilization of a substrate enabling a long range contact between the -5 phosphate (upstream to the scissile uracil) and the enzyme, and the results of modeling studies showing that the uracil-binding cavity of Y66W is wider than those of the wild type and other mutant UDGs, suggest a weaker interaction between uracil and the Y66W mutant. Furthermore, the fluorescence spectroscopy of UDGs and their complexes with Ugi, in the presence of uracil or its analog, 5-bromouracil, suggests compromised binding of uracil in the active site pocket of the Y66W mutant. Lack of inhibition of the Y66W UDG by apyrimidinic DNA (AP-DNA) is discussed to highlight a potential additional role of Y66 in shielding the toxic effects of AP-DNA, by lowering the rate of its release for subsequent recognition by an AP endonuclease.
尿嘧啶DNA糖基化酶(UDG)是一种普遍存在且高度特异性的酶,它启动尿嘧啶切除修复途径。结构研究表明,UDG高度保守的GQDPY水激活环中的酪氨酸会阻止胸腺嘧啶或嘌呤进入活性位点口袋。为了进一步了解该酪氨酸(大肠杆菌UDG中的Y66)的作用,我们过量表达并表征了Y66F、Y66H、Y66L和Y66W突变体。野生型、Y66F、Y66H和Y66L UDG与尿嘧啶DNA糖基化酶抑制剂(Ugi,一种蛋白质类底物模拟物)的复合物对8 M尿素稳定。然而,在该尿素浓度下,涉及Y66W UDG的复合物出现了一些解离。Y66L和Y66F突变体的催化效率(V(max)/K(m))与野生型UDG相似。然而,Y66W和Y66H突变体的活性分别降低了约7倍和约173倍。有趣的是,Y66W突变产生了一种对产物抑制有抗性的酶。优先利用一种能使-5磷酸(在可切割尿嘧啶上游)与酶之间形成远距离接触的底物,以及建模研究结果表明Y66W的尿嘧啶结合腔比野生型和其他突变型UDG的更宽,这表明尿嘧啶与Y66W突变体之间的相互作用较弱。此外,在尿嘧啶或其类似物5-溴尿嘧啶存在的情况下,UDG及其与Ugi复合物的荧光光谱表明Y66W突变体活性位点口袋中尿嘧啶的结合受损。本文讨论了无嘧啶DNA(AP-DNA)对Y66W UDG缺乏抑制作用,以突出Y66在通过降低其释放速率以供AP核酸内切酶后续识别来屏蔽AP-DNA毒性作用方面的潜在额外作用。